

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



23th October 2019

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400051.

Dear Sir,

Subject: Intimation to Stock Exchanges under Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Further to our letter dated October 17, 2019, with respect to the issuance of Equity Shares and Warrants convertible into Equity Shares on a preferential basis as well as issue of Preference Shares, we wish to inform you that the board of directors of the Company (the "Board") at its meeting held on October 23, 2019, subject to the approval of the shareholders of the Company, has approved:-

1. To increase the Authorized Share Capital of the Company from existing Rs. 20,00,00,000 (Rupees Twenty Crore only) divided into 2,00,00,000 (Two Crore) Equity Shares of Rs. 10 each to Rs. 53,00,00,000 (Rupees Fifty Three Crore only), comprising of:

- i. Rs. 23,00,00,000 (Rupees Twenty Three Crore) equity share capital divided into 2,30,00,000 (Two Crore Thirty Lakhs Equity Shares of Rs. 10/- each, and
- ii. Rs. 30,00,00,000 (Rupees Thirty Crore) preference share capital divided into 30,00,000 (Thirty Lakh Preference Shares) of Rs. 100/- each.

2. Issue of up to 17,05,000/- (Seventeen Lakh Five Thousand Only) Equity shares of Rs.10/- each for cash at a price of Rs. 86/- per Equity Share including premium of Rs. 76/- per share aggregating to Rs. 14,66,30,000/- to the following person/entity who form part of the promoter group ("proposed allottees") on preferential basis:

Name of the proposed allottee	No. of equity Shares proposed to be allotted
Mrs. Hemalatha Ravi	2,00,000
Ipca Laboratories Limited	15,05,000

3. Issue, on preferential basis, of upto 36,35,000 convertible warrants ("Warrant(s)") of Rs. 86/- each to Ipca Laboratories Limited, a promoter group entity, with right to the warrant holder to apply for and be allotted, per each warrant, 1 Equity Share of the face value of Rs. 10/- each of the Company ("Equity Shares") at a price of Rs. 86/- per Equity Share, including premium of Rs. 76/- per Equity Share, aggregating to Rs. Rs.31,26,10,000/- ,within a period of 18 (Eighteen) months from the date of allotment of the Warrants.



4. Issue, on preferential basis, upto 30,00,000, 9% Redeemable Non-Convertible Non- Cumulative Preference Shares of Rs. 100/- each aggregating to Rs. 30,00,00,000/- (Rupees Thirty Crores Only) to Ipca Laboratories Limited

5. Please note that an Extraordinary General Meeting of the Company will be held on 22nd November, 2019 to obtain shareholders approval for the above.

The proposed Issue will be undertaken in accordance with the provisions of chapter V of the SEBI ICDR Regulations and any other applicable rules / regulations / guidelines, if any, prescribed by any other statutory authorities.

The Board meeting started at 12.30 PM and concluded at 4.15 PM.

This is for the information of the Exchanges, please.

Thanking you,

Yours Faithfully

For **Krebs Biochemicals and Industries Limited**

Taruni Banda
Company Secretary

